What we do

 

Our mission at Mass General Brigham Ventures is to bring more bench-to bedside innovations to market to dramatically expand our positive impact on the quality of healthcare worldwide.  

Mass General Brigham Ventures invests exclusively in healthcare sector companies based on intellectual property created within our own research community.  We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.

Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support our portfolio companies through their entire financing lifecycles.

In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies.

Competitive

advantage

We have a privileged position to source technologies from Mass General Brigham's research and healthcare provider system, an exceptional advantage that conventional venture capital funds cannot reproduce.

* Listed are teaching hospitals affiliated with Harvard Medical School

  • $2.0 billion in annual research funding

  • 452 research and clinical departments

  • Over 6,200 principal investigators

  • $13.4 billion in annual revenue

  • Over 1,600 clinical trials

  • 3,700 faculty appointed at Harvard Medical School

We enjoy privileged access to the Mass General Brigham's intellectual property estate with the first look at newly disclosed inventions and the opportunity to work side-by-side with principal investigators across Mass General Brigham's network. In addition to this privileged deal flow, we also have an unparalleled interface with clinical and scientific expertise to support evaluation and due diligence investigation.   

  

Mass General Brigham is a widely acknowledged academic leader in scientific and clinical research. Our hospitals boast a history of medical firsts, including the use of TNF fusion protein for the treatment of rheumatoid arthritis (Enbrel®); elucidation of PD-1 receptor biology that spawned the field of immuno-oncology therapy; the discovery of  CRISPR gene-editing technology; and the targeting of EGFR gene mutations that enable high-efficacy personalized lung cancer therapy. ​

Annual Deal Flow

> 10,000

Scientific

Publications

> 500

Invention Disclosures

> 250

Patent

Filings

> 50

Qualified

Opportunities

4 - 6

NewCo

Investments